New anticancer drugs in Sweden
Previous studies have found that launch prices reflect the therapeutic gains of pharmaceuticals (for instance: Ekelund and Persson, 2003, on Sweden and Lu and Comanor, 1998, on the US). Furthermore, Howard et al (2015) found that purely pharmaceutical costs to “Medicare” at launch for new anticancer drugs increased annually, from 1995-2013, after controlling for health benefits and inflation. This
